BioSpace News Archive

Masimo announced that in a randomized controlled study involving 150 ICU patients recently published as a letter in Intensive Care Medicine, researchers investigated whether monitoring with Masimo ORi™ could reduce the time critically ill patients spend with moderate hyperoxia, compared to monitoring with oxygen saturation alone.

The Australian Government invests $40 million to provide patients affordable access to two new medicine listings through the Pharmaceutical Benefit Scheme (PBS)

CStone Pharmaceuticals announced that the first patient in China has been dosed in the Phase I/II bridging study of avapritinib, which was discovered by CStone’s partner Blueprint Medicines.

Arcadia Biosciences, Inc. announced a binding term sheet agreement with Arista Cereal Technologies and Bay State Milling Company for commercialization of its high fiber resistant starch wheat in key wheat markets, including North America, Europe and parts of Asia.

Arcadia Biosciences, Inc. announced that Raj Ketkar, president and CEO, will retire effective September 1, 2019.

By using single-cell analysis to measure metabolic activities in rare disseminated tumor cells taken from non-small cell lung cancer patients, Institute for Systems Biology researchers and their collaborators can accurately predict how patients will respond to various cancer therapies, and how treatments will impact a patient’s physiological performance and survival.

Cognate BioServices announced it has secured a financial sponsor to support its short-term and long-term growth as it closed on a round of growth capital from EW Healthcare Partners.

As the CDC reports that 69 percent of reported West Nile virus cases have been diagnosed with the more severe neuroinvasive disease, a scientific paper recently published in the peer-reviewed journal, Nature Communications, offers an explanation as to why some people infected with West Nile virus have no symptoms while others suffer life-threatening neuroinvasive disease.

Evofem Biosciences, Inc. announced the last patient has completed her last visit in AMPREVENCE, the Phase 2b clinical trial evaluating the Company’s lead product candidate Amphora®, a Multipurpose Vaginal pH Regulator, for the prevention of acquisition of chlamydia and gonorrhea in women.

MDxHealth SA announced that Palmetto GBA, a Medicare Administrative Contractor that assesses molecular diagnostic technologies under its MolDx program, has issued a draft local coverage determination for the SelectMDx® for Prostate Cancer test.